Kinase Chemistry – Just a year and a half behind the times.

clinical roundup

Posted by kinasepro on July 26, 2007

Supergen initiates dosing of flt3 inhibitor MP-470: ph1 ‘advanced-stage solid tumors.’

Entremed initiates trial for Aurora inihbitor MKC-1: Ph1 Leukemia

Kinex gets the FDA go-ahead for Src inhibitor KX2-391: lymphoma or solid tumors (though despite the press release, it’s not the first non-atp competitive kinase inhibitor to enter the clinic. The MEK inhibitors were)


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: